Table 1.
Clinical, pathological and molecular (HER2 positivity and MSI) features of the 142 patients with gastric cancer.
| Features | Cases | Percentage% |
|---|---|---|
| Age (mean and range) | 65.41 | 34–86 |
| ≤70 | 83 | 58.45% |
| ≥71 | 59 | 41.55% |
| Molecular characteristics | ||
| HER2-positive | 19 | 13.40% |
| MSI | 23 | 16.20% |
| Sex | ||
| Male | 89 | 62.70% |
| Female | 53 | 37.30% |
| Location | ||
| Cardia | 23 | 16.20% |
| Fundus | 1 | 0.70% |
| Corpus | 58 | 40.80% |
| Antrum | 59 | 41.50% |
| Histological type | ||
| Intestinal | 76 | 53.50% |
| Diffuse | 57 | 40.10% |
| Mixed | 9 | 6.40% |
| Pathological diagnosis | ||
| Adenocarcinoma | 104 | 73.20% |
| Signet ring cell carcinoma | 34 | 23.90% |
| Small cell carcinoma | 2 | 1.40% |
| Undifferentiated carcinoma | 1 | 0.70% |
| Squamous cell carcinoma | 1 | 0.70% |
| Degree of differentiation | ||
| G1 | 18 | 13.00% |
| G2 | 46 | 33.30% |
| G3 | 74 | 53.60% |
| T | ||
| Tis | 6 | 4.20% |
| T1a/T1b | 15 | 10.60% |
| T2 | 21 | 14.80% |
| T3 | 57 | 40.10% |
| T4a/T4b | 43 | 30.30% |
| N | ||
| N0 | 54 | 38.00% |
| N1 | 38 | 26.80% |
| N2 | 23 | 16.20% |
| N3a/N3b | 27 | 19.00% |
| M | ||
| M0 | 129 | 90.80% |
| M1 | 13 | 9.20% |
| Stage | ||
| IA/IB | 33 | 23.24% |
| IIA/IIB | 47 | 33.10% |
| IIIA/IIIB/IIIC | 46 | 32.40% |
| IV | 16 | 11.26% |
| Lymphatic involvement | ||
| Yes | 64 | 45.10% |
| No | 78 | 54.90% |
| Vascular involvement | ||
| Yes | 59 | 41.50% |
| No | 83 | 58.50% |
| Perineural involvement | ||
| Yes | 48 | 33.80% |
| No | 94 | 66.20% |
| Adjuvant chemotherapy | ||
| Yes | 43 | 30.30% |
| No | 99 | 69.70% |
| Survival | ||
| Living | 56 | 39.40% |
| Deceased | 86 | 60.60% |
HER2: Human Epidermal Growth Receptor 2, MSI: Microsatellite instability.